Comparative Pharmacology
Head-to-head clinical analysis: LO SIMPESSE versus MODEYSO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LO SIMPESSE versus MODEYSO.
LO SIMPESSE vs MODEYSO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bile acid sequestrant; binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby reducing enterohepatic circulation of bile acids and promoting conversion of cholesterol to bile acids in the liver, leading to decreased serum LDL cholesterol.
The mechanism of action of MODEYSO (elacestrant) is not fully elucidated. Elacestrant is an estrogen receptor antagonist that binds to estrogen receptor alpha (ERα) and degrades it, inhibiting estrogen-mediated signaling and tumor growth in ER-positive breast cancer.
100 mg orally once daily, with or without food.
400 mg orally once daily with food
None Documented
None Documented
Terminal elimination half-life is 12-16 hours in adults with normal renal function; may extend to >40 hours in severe renal impairment (CrCl <30 mL/min).
Terminal half-life approximately 6 days (range 4–10 days) in healthy subjects; supports weekly dosing interval
Primarily renal, with 70-80% of the dose excreted unchanged in urine; 10-20% via feces through biliary elimination.
Renal excretion unchanged: <1%; biliary/fecal elimination: >99% as unchanged drug
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive